Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2017 · 10-Q
Revenue$455.00K$455.00K+15.8% vs Q1 2016 Net Income-$21.99M-$21.99MN/M vs Q1 2016 EPS Diluted-$0.82-$0.82N/M vs Q1 2016 Operating Income-$22,922,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$20,410,000N/M Margins · derivedOperating margin-5037.8%−2175.0 pt vs Q1 2016
Net margin-4833.6%−2093.7 pt vs Q1 2016
ended Mar 31, 2017 · filed May 9, 2017 · 39 d after period end